B‐cell very late antigen‐4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity

Natalizumab, which binds very late antigen‐4 (VLA‐4), is a potent therapy for multiple sclerosis (MS). Studies have focused primarily upon its capacity to interfere with T‐cell migration into the central nervous system (CNS). B cells are important in MS pathogenesis and express high levels of VLA‐4....

Descripción completa

Detalles Bibliográficos
Autores principales: Lehmann‐Horn, Klaus, Sagan, Sharon A., Bernard, Claude C.A., Sobel, Raymond A., Zamvil, Scott S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405474/
https://www.ncbi.nlm.nih.gov/pubmed/25712734
http://dx.doi.org/10.1002/ana.24387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405474/
https://www.ncbi.nlm.nih.gov/pubmed/25712734
http://dx.doi.org/10.1002/ana.24387

Ejemplares similares